- Chimerix (CMRX +10.5%) has agreed to provide its Brincidofovir (CMX001) treatment to a seven-year-old boy who is dying from an adenovirus infection after his immune system was weakened by a bone-marrow transplant.
- Chimerex had initially refused to supply the drug, as it's not approved, but caved in after huge pressure in the media.
- The company will make the boy, named Josh Hardy, the first patient in a 20-patient pilot trial, with the FDA saying it will help the firm design a Phase III study that could be launched as a continuation of the pilot. (PR)
Chimerex to supply unapproved drug to try to save dying boy
This was corrected on 04/09/2014 at 09:39 AM.
From other sites
at Zacks.com (Mar 5, 2015)
at CNBC.com (Jan 14, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Dec 31, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs